Open AccessSWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
Author(s) -
Evan Y. Yu,
Hongli Li,
Celestia S. Higano,
Neeraj Agarwal,
Sumanta K. Pal,
Ajjai Alva,
Elisabeth I. Heath,
Elaine T. Lam,
Shilpa Gupta,
Michael B. Lilly,
Yoshio Inoue,
Kim N.,
Nicholas J. Vogelzang,
David I. Quinn,
Heather H. Cheng,
Stephen R. Plymate,
Maha Hussain,
Catherine M. Tangen,
Ian M. Thompson
Publication year - 2015
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2014.59.4127
Subject(s) - medicine , bicalutamide , prostate cancer , tolerability , androgen deprivation therapy , clinical endpoint , oncology , prostate specific antigen , triptorelin , urology , androgen receptor , luteinizing hormone , hormone , cancer , endocrinology , randomized controlled trial , adverse effect , gonadotropin releasing hormone
Cixutumumab, formerly IMC-A12, is a recombinant human monoclonal immunoglobulin G1 antibody that targets insulin-like growth factor I receptor (IGF-IR). Cixutumumab was synergistic with castration in a hormone-sensitive prostate cancer xenograft model.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom